# Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

> **NCT07678580** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Albumin-bound paclitaxel
- **RADIATION:** Low-dose Short-course Radiotherapy
- **RADIATION:** High-dose Short-course Radiotherapy
- **DRUG:** Tislelizumab Combined With Chemotherapy for 3 cycles
- **DRUG:** Carboplatin (AUC 5)

## Key facts

- **NCT ID:** NCT07678580
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2028-01-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678580, "Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*